12th Annual Peptide Therapeutics Symposium, October 2017
Cellular Manipulation through Cell Penetrating Peptide-Loaded Exosome Transfer
A Novel One-Pot Synthesis Strategy for Bicyclic Peptide Assembly
ORBIT Peptide Display—High throughput Selection of Peptides with Biological Function
Efficient Cell Aelivery and Lipid-specific Endosomal Escape by Aupercharged Peptides
Effect of a Fusion Peptide by Covalent Conjugation of a Mitochondrial Cell-penetrating Peptide and a Glutathione Analog Peptide
MOE Coupled with AutoDock Vina Molecular Docking and Virtual Screening Empowered Discovery of Tetrapeptides Inhibitors of Y-49 β-Lactamase
Genetically Encoded Discovery of Chemically-Modified Peptides
Scaffold-based Citrullinated Peptides for Inhibition of Autoantibodies in Rheumatoid Arthritis
Towards Mild and Selective Incorporation of Freidinger Lactams into Expressed Peptides
GUB06-046, a Novel Secretin/GLP-1 Co-Agonist, Decreases Food Intake, Improves Glycemic Control and Preserves Beta Cell Mass in db/db Mice
Machine Learning Techniques for Peptide Optimization from Sequence Information
Fast Synthesis of 84-mer Human Parathyroid Hormone for the Study of Osteoporosis and Hypoparathyroidism
A Novel Tri-Peptide Elicits Cardioprotective Effects in Myocardial Ischemia/Reperfusion Injury by an Opioid Receptor Mechanism
Designing Cell-material Interactions by Controlling the Chemistry of the Surface of Degradable Porous Scaffolds
Modulation of Quorum Sensing in Streptococcus pneumoniae; An Alternative Approach to Antimicrobial Therapy
Characterizing the Impact of the Highly Endosomolytic Cell-Penetrating Peptide, dfTAT, on
Investigation of Novel Cyclic Peptides for Preferential Binding to Melanocortin 4 Receptors
Mapping Membrane Activity in Undiscovered Peptide Sequence Space Using Machine Learning
On the Effects of Acylation of Cell-penetrating Peptides in Nucleic Acid Delivery In Vitro and In Vivo
Effective Prediction of Long-term Stability and Aggregation Propensity of Proteins via Differential Scanning Calorimetry (DSC)
Evaluation of Apelin-13 Analogues as Antidiabetic Therapeutics
Myristoylated Protein Kinase C Epsilon Peptide Inhibitor Reduces Infarct Size and Improves Cardiac Function Following Myocardial Ischemia/Reperfusion (I/R)
CPP and Small Molecule Synergy Enhances Endosomal Escape and Cytosolic Delivery in Live Cells
Optimizing Peptide Manufacturing on the Small Scale and its Application in the Rapid Development of New Personalized Medicines
Novel Therapeutic Peptides Targeting Matricellular Signaling in Currently Untreatable Fibrotic Disease and Cancer
Improved Florescent Amino Acids For In Situ Labeling of Bacterial Cell Walls
Development of a New Method on Npys-based Disulfide Bond Formation for the Preparation of Bioactive Cyclic Disulfide Peptides
Discovery of Selective Hexapeptide Agonists to Human NMUR1 and NMUR2
Highly Efficient Synthesis of Therapeutic Macrocyles by Ligases
Computational Design and Experimental Characterization of Peptides Intended for pH-Dependent Membrane Insertion and Pore Formation
Plasma Protein Binding Analysis of Peptides with a Novel Single-compartment Mass Spectrometry Assay
Targeting Quorum Sensing in Streptococcus Pneumoniae: An Alternative Antibacterial Approach
N-linked Glycosylation Prevents Deamidation of Glycopeptide and Glycoprotein
Structure-Based Design, Synthesis and Evaluation of Constrained Seven Membered Ring-Containing Tetrapeptides Lead to Selective Human Melanocortin 1 Receptor
11th Annual Peptide Therapeutics Symposium, October 2016
Asprosin, a Fasting-Induced Glucogenic and Orexigenic Protein Hormone
Tailoring Peptides for less Frequent Dosing and Non-invasive Delivery
Non- Peptide GLP-1 Receptor Agonists; From Idea to Medicine
Structural Elucidation of Ligand Binding Sites in Class B GPCRs and their Application in Drug Discovery
Selective Inhibition of Cytokines with Peptide Therapeutics: A Unique Alternative to Conventional MAB and JAK Inhibitor Approaches for Cytokine Modulation
Peptide-based Strategies to Treat Inflammatory and Autoimmune Diseases: From the Peptide P140 to Lupuzor™
Innovation by Evolution: Expanding the Enzyme Universe
Novel Synthetic Strategies for Insulin and Related Peptides
AB103: Host-Oriented Therapeutics to Control Life Threatening Infections
Engineering Potent and Selective Inhibitors of Nav1.7 Sodium Channel
Taregting Novel Polysaccharide-binding Proteins to Block Tissue Fibrosis
TLQP-21 and C3aR1, a Novel Ligand/Receptor Target for Lipolysis and Obesity
Discovery and Clinical Development of Elamipretide
Unlocking the Mysteries of Amyloid Diseases with Macrocyclic β-Sheet Peptides
Endocrine FGFs and Structure-Activity-Relationship
New Therapeutics from the Human Microbiome: Discovery of Novel Proteins and Peptides for the Treatment of Gastrointestinal Barrier Related Disorders
Chemo-enzymatic Peptide Synthesis (CEPS): A Generally Applicable, Traceless Ligation Technology for the Synthesis of Peptide-to-peptide and Peptide-to-protein Conjugates
InGell® – Injectable Drug Depots for Short and Mid-term Release of Soluble and Non-soluble API’s
Errata located at the end of the Symposium PDF
10th Annual Peptide Therapeutics Symposium, October 2015
Building Better Medicines: Translational Research in the 21st Century
An Integrated View of the Adipocyte: From Feast to Famine
Oral Peptide Delivery: Deciphering the Reality from the Hype
Oral Inhalation – A Simple Approach to Biologics Delivery
ITCA 650 (Exenatide Delivered Continuously via a Matchstick-Size Subcutaneous
MICROCOR® Transdermal System: Technology Overview and Clinical Status
Activity-based Proteomics – Applications for Enzyme and Inhibitor Discovery
Molecular Targets for the Effects of Bariatric Surgery on Obesity and Diabetes
Harnessing Chemistry and Glycoproteins to Discover Novel Targets for Cancer
Engineered Cystine Knot Peptides: A New Class of Tumor Targeting Agents
Phage Selection of Bicyclic Peptides for Application as Therapeutics
Kisspeptin and its Short-length Agonist Analogues: Discovery and Development
Phage-display Derived Peptidic Inhibitors of PCSK9 for LDL Cholesterol Lowering
Improved Chemical and Physical Stability in Liquid Formulations – How to Design
Selepressin, a Selective hV1a Agonist for the Treatment of Hypotension in Septic Shock
Addressing the Challenges with the Discovery and Development of Peptide
NA-1: From Bench to Bedside – A Novel Peptide Therapeutic for the Treatment of
Relamorelin, a Ghrelin Agonist for the Treatment of Diverse Functional
9th Annual Peptide Therapeutics Symposium, October 2014
Multiselective Peptides for the Treatment of Metabolic Diseases by Cristina Rondinone, Ph.D., Vice President, Research and Development, Head Cardiovascular/Metabolic Diseases iMED, Medimunne
Peptide Agonists of Incretin Receptors Are High Priority Candidates in the Search for the First Effective Treatments of Alzheimer’s Disease by Konrad Talbot, Ph.D., Associate Professor, Department of Neurosurgery, Cedars-Sinai Medical Center
Continuous Glucose Monitoring: Technology that will Bridge the Gap until there is a Cure for Type 1 Diabetes by Steven Edelman, M.D., Professor of Medicine, University of California San Diego, Veterans Affairs Medical Center , Founder and Director, Taking Control of Your Diabetes 501(c)3
Peptide Therapeutics: A New Golden Age by Richard A. Houghten, Ph.D., Founder, President & CEO, Torrey Pines Institute for Molecular Studies
New Physiology and Pharmacology of the Melanocortin-4 Receptor by Roger D. Cone, Ph.D.,Professor and Chair, Department of Molecular Physiology and Biophysics, Vanderbilt University Medical Center
Chemoenzymatic Approaches in Amide-to-amide Peptide Ligation by James P. Tam, Ph.D. , Professor, Herbalomics and Drug Discovery, School of Biological Sciences, Nanyang Technological University
Hepcidin and Minihepcidins: From Mechanistic Studies to Therapeutic Peptides by Tomas Ganz, Ph.D., M.D., Professor of Medicine and Pathology, University of California, Los Angeles
Discovery of Functional Ligands and Materials from Genetically-encoded Libraries of Chemically-modified Peptides by Ratmir Derda, Ph.D.,Assistant Professor, Department of Chemistry and Alberta Glycomics Centre, University of Alberta
Using the Endosome Escape Trap to Discover Phylomer Peptides which more Efficiently Deliver Cargoes to the Cytoplasm by Paul Watt, D.Phil., Chief Scientific Officer, Phylogica Ltd
Danegaptide – Potential First and Best in Class Peptide Medicine for Prevention of Myocardial Reperfusion Injury by Rie Schultz Hansen, MSc, Ph.D. , Principal Scientist, Zealand Pharma A/S
Arylomycin Antibiotics by Floyd E. Romesberg, Ph.D., Assistant Professor, Department of Chemistry The Scripps Research Institute
Novel Peptide Therapeutics Targeting Key Intracellular Signaling Pathways of Cancer Stem Cells by Jörg Vollmer, Ph.D., Managing Director and Chief Executive Officer, Nexigen GmbH
Peptide Antagonists of the Inflammatory Response Enhanced by the Antimicrobial Peptide LL-37 by Cheng Kao, Ph.D. , Director of Biotechnology and Professor, Department of Molecular & Cellular Biology, Indiana University
Integrated Triple Gut Hormone Action Broadens the Therapeutic Potential of Endocrine Biologics for Metabolic Diseases by Brian Finan, Ph.D. Division Head, Helmholtz Zentrum Munich
8th Annual Peptide Therapeutics Symposium, October 2013
The Structural and Energetic Basis of Carbohydrate–Polypeptide Stabilizing Interactions Within Enhanced Aromatic Sequons in Protein Native States by Jeffery W. Kelly, The Scripps Research Institute
Developing IMS-MS Techniques as a means of Following Structural Transitions of Biopolymers in Solution by David E. Clemmer, Indiana University
Half-Life Extension Through HESylation® by Martin Meyer, Fresenius Kabi Deutschland GmbH
Long-acting Release of Drug Peptides by in situ Gelling FluidCrystal® Injection Depot by Fredrik Tiberg, Camurus AB
The Transdermal Delivery of Peptides and other Biotherapeutics by Frank Tagliaferri, 4P Therapeutics
Structural Insights into HIV, Influenza & HCV Antigen Design by Ian A. Wilson, The Scripps Research Institute
How Insulin Binds: Structure of a Micro-receptor Complex and Implications for Analog Design by Michael A. Weiss, Case Western Reserve University
Mimicry of Hormone Recognition Surfaces with Peptidic Foldamers by Samuel H. Gellman, University of Wisconsin, Madison
ShK-186, a Peptide Inhibitor of Kv1.3 Potassium Channels as Therapy for Autoimmune Diseases and Metabolic Syndrome by K. George Chandy, University of California, Irvine
The Tale of Two Peptides Rescuing a Company in Distress by Roger J. Garceau, NPS Pharmaceuticals, Inc.
Towards Optimized Utility of Proteasome Inhibitors with Peptide Epoxyketones by Christopher J. Kirk, Onyx Pharmaceuticals, Inc.
Direct Selection of Highly Potent Cyclic Peptidomimetics from In Vitro Display Libraries by Douglas A. Treco, Ra Pharmaceuticals, Inc.
Development of Serelaxin for Acute Heart Failure by Dennis Stewart, Corthera Inc., Novartis Pharmaceuticals Corp.
SOM230: A New Therapeutic Modality for Cushing’s Disease by Ian Lewis, Novartis Institutes of Biomedical Research
PeptiDream’s PD Platform: Innovative Peptide Discovery Platform by Patrick C. Reid, Peptidream Inc.
Design of Peptide Therapeutics Exhibiting Dual Pharmacology and Extended Duration of Action by Soumitra Ghosh, Amylin Pharmaceuticals LLC
The Development of BA058, a Novel Peptide, for the Treatment of Osteoporosis by Gary Hattersley, Radius Health, Inc.
99mTc-Galacto-RGD2: A novel 99mTc-Labeled Cyclic RGD, Peptide Dimer Useful for Tumor Imaging by Michael Pennington, Peptides International, Inc.
7th Annual Peptide Therapeutics Symposium, October 2012
Chemoselective Strategies for the Synthesis of Complex Assemblies of Peptide by
Cell-penetrating Peptides with Intrinsic Biological Activity by Francesca Milletti, Ph.D., Head, Cheminformatics & Statistics, Roche Pharmaceuticals
Peptide Macrocyclization Enabled by Amphoteric Molecules by Andrei K. Yudin, Ph.D., Professor, Davenport Research Laboratories, Chemistry Department,
The State of Pharmaceutical Innovation by Bernard Munos, MBA, Founder, InnoThink Center for Research in Biomedical Innovation
Design of Therapeutics that Act on Membranes and Membrane Proteins by Bill DeGrado, Ph.D., Professor, Department of Pharmaceutical Chemistry; Investigator, Cardiovascular
Gut-peptide Based Poly-pharmacy for the Treatment of Obesity & Diabetes by Matthias Tschöp, M.D., Alexander-von-Humboldt Professor; Director, Institute for Diabetes and
Omontys: Beating the Odds in the Journey of a Drug from Bench to Bedside
Identification and Characterization of KAI-4169, A Novel Peptide for the Treatment
Stapled Peptide Drugs: Translation to the Clinic by Tomi K. Sawyer, Ph.D., Chief Scientific Officer and Senior-Vice President, Drug Discovery and Innovative
LY2605541, a Novel Long-acting Basal Insulin by Mel Prince, M.D. Senior Medical Director, Lilly Diabetes, Eli Lilly and Company
NMDA Receptor Modulating Peptides with Therapeutic Potential: From Monoclonal Antibodies to the Creation and Development of GLYX-13 by Joseph R. Moskal, Ph.D., Professor and Director, The Falk Center for Molecular Therapeutics, McCormick School of Engineering and Applied Sciences, Dept. of Biomedical Engineering, Northwestern University
XEP-018: A New Myorelaxant Peptide Lead Compound from the Venom of the
XTENylation Offers a Biodegradable Alternative to PEGylation by Volker Schellenberger, Ph.D., Chief Scientific Officer, Amunix, Inc.
Tunable Half-life Extension of Therapeutics by Controlled Chemical Release from
Development of Modified Human Serum Albumins for Peptide and Protein Half-life Extension: Towards Monthly Dosing by Mark Perkins, Ph.D., Customer Solutions Manager, Novozymes Biopharma UK Ltd.
Clinical Development of a Novel PTH Analog for the Treatment of Osteoporosis with an
6th Annual Peptide Therapeutics Symposium, October 2011
Discussion about factors driving R&D funding today
Development of a Long-acting C-peptide (ErsattaÔ) by James Callaway, Ph.D. President and CEO, Cebix Incorporated
Long Acting Y2R Peptide Mimetic as a New Generation Therapeutic Agent for the Management of T2D by Waleed Danho, Ph.D., Distinguished Research Leader, Hoffmann- La Roche Inc.
Somatostatin-Dopamine Chimeric Molecule for Potential Treatment of Pituitary Adenomas and Neuroendocrine Tumors by Jesse Z. Dong, Ph.D., Director, Peptide Therapeutics Foundation, Vice President, Compound Discovery, Ipsen
Targeting Protein Therapeutics Across the Blood-Brain Barrier with Molecular Trojan Horses by William M. Pardridge, Ph.D., Distinguished Professor of Medicine, University of California, Los Angeles
Neuropeptidomics: From the Discovery of New Neuropeptides to the Elucidation of their Functions by Jonathan Sweedler, Ph.D., Professor of Chemistry, James R. Eiszner Family Chair, University of Illinois, Urbana-Champaign
Comparative Peptidomic Analysis for Functional Discovery of Neuropeptides by Lingjun Li, Ph.D., Professor, School of Pharmacy and Department of Chemistry, University of Wisconsin
High Resolution Mass Spectrometry-Based Profiling of Secreted Peptides for Drug Discovery by Steven Taylor, Ph.D.
EPiC Technology: Using Peptide to Physiologically Cross the BBB by Jean Paul Castaigne, M.D., MBA, President and CEO, AngioChem
Endogenous Peptides to Safely Enhance the Delivery of (peptide) Drugs to the Brain by Willem van Werperen, MSc, MBA, CEO, to-BBB
Enhancing CNS Uptake of Biologics through Molecular Engineering by Ryan Watts, Ph.D., Associate Director, Head of Neurodegeneration Labs, Department of Neuroscience, Genentech, Inc.
NPY2R Selective Peptide Agonists for the Treatment of Obesity: Balancing Efficacy, Time Action and Cardiovascular Profile by Jordi Alsina, Ph.D., Senior Research Scientist, Eli Lilly & Company
Development Of CR845, a Novel, Peripherally-Acting Peptidic Kappa Opioid Agonist, for the Treatment of Postoperative Pain by Derek Chalmers, Ph.D., D.Sc., President & CEO, Cara Therapeutics, Inc.
ZYPH0907: A Novel Orally Active PTH1R Agonist for Treatment of Osteoporosis by Mukul Jain, Ph.D.,Senior Vice President, ZydusResearch Center
5th Annual Peptide Therapeutics Symposium, October 2010
Venture Capital panel discussion: Attractive Financing Structures for Emerging Biotechnology Companies.
Chemical Synthesis in the Development of Protein Therapeutics by Stephen B.H. Kent, Ph.D., Professor, Department of Chemistry, University of Chicago
Chemically Programmed Immunity: Making Peptides Drugs and More by Carlos Barbas III, Ph.D., Janet and Keith Kellogg II Chair in Molecular Biology Professor, Department of Molecular Biology, The Scripps Research Institute
Tumor-penetrating Peptides in Targeted Tumor Treatment by Erkki Ruoslahti, M.D., Ph.D., Distinguished Professor, Sanford-Burnham Medical Research Institute
Glioblastoma: Cancer Stem Cells and Reprogramming by Inder Verma, Ph.D., Professor, Irwin and Joan Jacobs Chair in Exemplary Life Science, Laboratory of Genetics and American Cancer Society Professor of Molecular Biology, Salk Institute for Biological Studies
From Combinatorial Chemistry to Nanoparticles to Cancer Imaging and Therapy by Kit Lam, M.D., Professor and Chief, Hematology and Oncology, University of California Davis Cancer Center
Protein Engineering: A Key Innovation Path for Novel Biopharmaceuticals by Thomas Bumol, Ph.D., President, Applied Molecular Evolution & Vice President Biotechnology, Lilly Research Laboratory
Early Clinical Development of Novel Biologics by Richard Jones, M.D., Chief Medical Officer, Syntaxin
Ligand-receptor Fusions for the Generation of Long-acting Biopharmaceuticals by Richard Ross, M.D., Chief Scientific Officer and Director, Asterion
Antibody Drug Conjugates: Current and Future Developments by Hans-Peter Gerber, Ph.D., Senior Director Pfizer
Enhancing the Activities of Monoclonal Antibodies for Cancer Therapy by Peter Senter, Ph.D., Vice President Chemistry, Seattle Genetics
New Horizons in Protein Medicinal Chemistry Enabled with an Expanded Genetic Code by Ho Sung Cho, Ph.D., Chief Technical Officer, Ambrx Inc.
4th Annual Peptide Therapeutics Symposium, November 2009
Update on development trends for peptide therapeutics by Janice M. Reichert, Ph.D., Senior Research Fellow, Tufts Center for the Study of Drug Development.
New Targets and Targeting Mechanisms for Contrast Agents and Therapeutics by Roger Tsien, Ph.D., HHMI Investigator& 2008 Nobel Laureate Chemistry, Professor Pharmacology, Chemistry and Biochemistry, UCSD.
NMR structural studies of drug receptors in membranes by Stanley Opella, Ph.D., Professor Chemistry and Biochemistry & Director Nuclear Magnetic Resonance Resource Lab, UCSD.
Peptide transduction domain mediated delivery of macromolecules; Tackling the siRNA delivery problem by Steven F. Dowdy, Ph.D., HHMI Investigator & Professor Cellular and Molecular Medicine, School of Medicine, UCSD
Peptide inhibitors of protein-protein interactions; From rational design to the clinic by Daria Mochly-Rosen, Ph.D., Professor, Chemical and Systems Biology & Senior Associate Dean for Research, School of Medicine, Stanford University.
Stapled helical peptides: A new drug modality by Noriyuki Kawahata Ph.D., Senior Principal Scientist Chemistry, Aileron Therapeutics.
Clinically validated inhibitors of intracellular protein interactions by Stephen D. Harrison, Ph.D., Senior Vice President, Research, Kai Pharmaceuticals.
Pepducins – Novel mediators of GPCR signaling by Stephen Hunt, Ph.D., Senior Vice President, Discovery Research, Ascent Therapeutics.
Linaclotide: A potential therapy for IBS-C by Mark G. Currie, Ph.D., Senior Vice President, R&D & CSO, Ironwood Pharmaceuticals Inc.
Non-Invasive systemic delivery of peptides with high bioavailability by Edward T. Maggio, Ph.D., CEO & Director, Aegis Therapeutics.
3rd Annual Peptide Therapeutics Symposium, October 2008
CovX-Body Biotherapeutics: From Concept to Applications by Joel Desharnais, Ph.D. Senior Scientist, CovX
Sustained Release of Peptides Using Microencapsulation and the Development of Long Acting Exenatide by Paul Herbert, Vice President Process Development Alkermes , Inc.
Engineering Kunitz Domains Using Phage Display by Andrew E. Nixon, Ph.D., Vice President, Lead Discovery and Biochemistry, Dyax Corporation
Preformed Conjugate-Drug Affinity Complex (PC-DAC™) Technology by Martin Robitaille, Ph.D., Director, Peptide Chemistry, Conjuchem Biotechnologies, Inc.
Trends in the Clinical Development and Approval of Synthetic Peptides by Janice Reichert, Ph.D., Senior Research Fellow, Tufts Center for the Study of Drug Development
2nd Annual Peptide Therapeutics Symposium, November 2007
Building, Understanding and Leveraging a Peptide Library by Michael Hanley, Ph.D., Vice President Discovery Research, Amylin Pharmaceuticals
Application of Chemical Biotechnology to the Optimization of Protein Therapeutics by Richard Dimarchi, Ph.D., Professor, Department of Medicinal Chemistry, Indiana University
Degarelix: a novel GnRH antagonist for the treatment of prostate cancer by Per Cantor, M.D., Ph.D., Senior Vice President Clinical and Non-Clinical Development, Ferring Pharmaceuticals
KL-4 Surfactant – Form to Function by Charles Cochrane, M.D., Professor, Department of Immunology, The Scripps Research Institute
The Commercialization of Fuzeon® API by Brad DeHoff, Ph.D., Technical Manager, Roche Colorado Corp.
The Beta Cell Hormone Amylin: Discovery and Clinical Application by Andrew Young, M.D., Ph.D., Vice President , Senior Research Fellow, Amylin Pharmaceuticals
“Ynot Y2 and Y4 Peptide Agonists for Treatment of Diabetes and Obesity?” by Thue Schwartz, M.D., CSO, 7TM Pharma, University of Copenhagen
Oxyntomodulin or Products of the PYY Preproglucagon gene by Steve Bloom, M.D., Professor of Medicine, Imperial College, London
1st Annual Peptide Therapeutics Symposium, November 2006
Medicinal Chemistry of Peptide Hormones by Victor Hruby, Ph.D., Regents Professor of Chemistry, University of Arizona
GnRH: a Peptide for All Seasons by Robert Millar, Ph.D., Director, MRC Human Reproductive Sciences Unit, Ardana
Desmopressin, a Selective Antidiuretic Analog of Vasopressin by Jens Peter Norgaard, Ph.D., CSO, Urology, Ferring Pharmaceuticals
History of the Development of Byetta: The Vicissitudes of Drug Development in Biotechnology by Alain D. Baron, Ph.D., Sr. Vice President, Research, Amylin Pharmaceuticals
Clinical Applications of the GLP-2 Analogue Teduglutide by Derek Chalmers, Ph.D., President & CEO, Cara Therapeutics
Current Status of Methods for Large-Scale Production of Peptides Michael Verlander, Executive Vice President, Ph.D., Polypeptide Laboratories, Inc.
For more information regarding Symposiums 1-5, please contact us.
Stéphane Bolduc – CHU de Québec – Université Laval Research Center
Marcello Costa – Flinders University
Warren Foster – University of California, San Diego
Andrew Horne – University of Edinburgh
K. Joseph Hurt – University of Colorado
Ursula Kaiser – Brigham and Women’s Hospital, Harvard Medical School
Sarah Marshall – Monash University
Kathryn Meier – Washington State University
Victor Navarro – Brigham and Women’s Hospital, Harvard Medical School
Willis Samson – Saint Louis University, School of Medicine
John Taylor – Kansas University Medical Center
Suraj Unniappan – University of Saskatchewan
Henrique Veiga-Fernandes – Champalimaud Foundation
Meet the 2016 Recipients
October 25-26, 2018
The Salk Institute